Cancer is a major global health threat and a leading cause of mortality worldwide. Nucleotide analog chemodrugs are commonly used in the treatment of various solid tumors, but their clinical efficacy is often limited by rapid blood metabolization, poor intracellular diffusion and significant side effects due to non-selectivity targeting. To address these challenges, this study investigates the potential of conjugating squalenea natural triterpene and cholesterol biosynthesis precursorto two model chemodrugs to enhance the drug's incorporation into endogenous low-density lipoproteins (LDLs) for targeted cancer delivery. By leveraging the natural affinity of lipoproteins for cancer cells with overexpressed lipoprotein receptors, this approach can potentially improve the drugs specificity to cancer cells and accumulation at tumor sites. Using molecular dynamics (MD) simulations, we found that squalene-conjugated drugs have favorable partitioning into LDL interior with a deep negative free energy well. It confirms that squalene-drug conjugates possess the significantly higher affinity to LDL and the potential to exploit LDL for targeting cancer cells. The improved drug behaviors are expected to improve drug circulation and tumor accumulation. The findings provide valuable insights into the potential of squalene-conjugated chemodrugs as a novel strategy for improving the therapeutic efficacy of nucleoside analogs in cancer treatment
Read full abstract